WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (NASDAQ:IMGN), a biotechnology
company that develops targeted anticancer therapies using its industry
leading antibody-drug conjugate (ADC) technology, today announced the
appointment of Eric Guempel as Vice President of Product Strategy and
Program Management. Mr. Guempel brings to ImmunoGen more than 30 years
of experience in the healthcare industry, including extensive experience
in commercial functions related to the strategic development of novel
oncology products. He reports to Dr. Charles Morris, Executive Vice
President and Chief Development Officer of ImmunoGen.
"Eric joins ImmunoGen in a new position we established to enhance the
strategic leadership of our proprietary programs, ensuring that as we
advance our clinical compounds through proof of concept we implement
development strategies for each compound that align with patient and
market needs," commented Dr. Morris.
Mr. Guempel has extensive experience leading cross-functional oncology
product teams. He joins ImmunoGen from the Merck Serono division of
Merck KGaA, where he was Head of New Therapies and Strategy for the
Oncology Franchise. Prior to joining EMD Serono in 2008, Mr. Guempel
held positions of increasing responsibility in the Oncology Strategic
Business unit of Biogen Idec, including the position of Rituxan®
Team Leader. Prior to joining Idec in 2002, he held commercial positions
supporting Neupogen®, Neulasta® and other oncology
programs at Amgen. Prior to joining the marketing functions in 1998, Mr.
Guempel held clinical research-related positions of increasing
responsibility at Amgen, Berlex, and Ciba-Geigy (now Novartis). He holds
an MS degree in Biology from Seton Hall University and an MBA from
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses a tumor-targeting engineered antibody to deliver one
of ImmunoGen's highly potent cancer-cell killing agents specifically to
tumor cells; the Company has also developed antibodies with anticancer
activity of their own. The most advanced compound with ImmunoGen's ADC
technology is Roche's Kadcyla®, which is marketed in the US
by Genentech and is also gaining approvals internationally. Additional
compounds are in clinical testing by ImmunoGen and through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla®, Rituxan®, Neupogen® and
Neulasta® are registered trademarks of their respective
Source: ImmunoGen, Inc.